Literature DB >> 24859437

Targeted nanoparticles for simultaneous delivery of chemotherapeutic and hyperthermia agents--an in vitro study.

Supriya Srinivasan1, Romila Manchanda2, Tingjun Lei3, Abhignyan Nagesetti1, Alicia Fernandez-Fernandez4, Anthony J McGoron5.   

Abstract

The purpose of this study was to prepare targeted Poly lactide-co-glycolide (PLGA) nanoparticles with simultaneous entrapment of indocyanine green (ICG) and doxorubicin (DOX) by surface decorating them with tumor specific monoclonal antibodies in order to achieve simultaneous therapy and imaging. ICG was chosen as an imaging and hyperthermia agent and DOX was used as a chemotherapeutic agent. ICG and DOX were incorporated into PLGA nanoparticles using the oil-in-water emulsion solvent evaporation technique. These nanoparticles were further surface decorated with antibodies against Human Epithelial Receptor-2 (HER-2) using carbodiimide chemistry. The uptake of antibody conjugated ICG-DOX-PLGA nanoparticles (AIDNP) was enhanced in SKOV-3 (HER-2 overexpressing cell lines) compared to their non-conjugated counterparts (ICG-DOX-PLGA nanoparticles (IDNP)). The uptake of antibody conjugated ICG-DOX-PLGA nanoparticles, however, was similar in MES-SA and MES-SA/Dx5 cancer cells (HER-2 negative cell lines), which were used as negative controls. The cytotoxicity results after laser treatment (808 nm, 6.7 W/cm(2)) showed an enhanced toxicity in treatment of SKOV-3. The negative controls exhibited comparable cytotoxicity with or without exposure to the laser. Thus, this study showed that these antibody conjugated ICG-DOX-PLGA nanoparticles have potential for combinatorial chemotherapy and hyperthermia.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Doxorubicin; Drug delivery; Hyperthermia; Image-guided therapy; Indocyanine green; Molecular imaging; Theranostics

Mesh:

Substances:

Year:  2014        PMID: 24859437     DOI: 10.1016/j.jphotobiol.2014.04.012

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  8 in total

1.  IR820-loaded PLGA nanoparticles for photothermal therapy of triple-negative breast cancer.

Authors:  Danielle M Valcourt; Megan N Dang; Emily S Day
Journal:  J Biomed Mater Res A       Date:  2019-04-09       Impact factor: 4.396

2.  Multifunctional organically modified silica nanoparticles for chemotherapy, adjuvant hyperthermia and near infrared imaging.

Authors:  Abhignyan Nagesetti; Anthony J McGoron
Journal:  Colloids Surf B Biointerfaces       Date:  2016-08-18       Impact factor: 5.268

3.  Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.

Authors:  Danielle M Valcourt; Megan N Dang; Mackenzie A Scully; Emily S Day
Journal:  ACS Nano       Date:  2020-02-26       Impact factor: 15.881

4.  Engineering functionalized multi-phased silicon/silicon oxide nano-biomaterials to passivate the aggressive proliferation of cancer.

Authors:  P Premnath; B Tan; K Venkatakrishnan
Journal:  Sci Rep       Date:  2015-07-20       Impact factor: 4.379

5.  Covalent IR820-PEG-diamine nanoconjugates for theranostic applications in cancer.

Authors:  Alicia Fernandez-Fernandez; Romila Manchanda; Denny A Carvajal; Tingjun Lei; Supriya Srinivasan; Anthony J McGoron
Journal:  Int J Nanomedicine       Date:  2014-10-06

Review 6.  Leveraging Engineering of Indocyanine Green-Encapsulated Polymeric Nanocomposites for Biomedical Applications.

Authors:  Ya-Hui Han; Ranjith Kumar Kankala; Shi-Bin Wang; Ai-Zheng Chen
Journal:  Nanomaterials (Basel)       Date:  2018-05-24       Impact factor: 5.076

Review 7.  Cytotoxicity of targeted PLGA nanoparticles: a systematic review.

Authors:  Hock Ing Chiu; Nozlena Abdul Samad; Lizhen Fang; Vuanghao Lim
Journal:  RSC Adv       Date:  2021-03-03       Impact factor: 3.361

8.  Dual Regulation of miR-34a and Notch Signaling in Triple-Negative Breast Cancer by Antibody/miRNA Nanocarriers.

Authors:  Danielle M Valcourt; Emily S Day
Journal:  Mol Ther Nucleic Acids       Date:  2020-06-09       Impact factor: 10.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.